FDA Likely to Make Decision on Mercury Fillings by July 2009
We Think Outright Ban is Unlikely

- This week, the FDA responded to the district court in Washington, DC, which had ordered the agency to provide a date by which it will issue classification standards for mercury (i.e. amalgam) fillings. As a reminder, medical devices are classified under a three-tiered system (I, II, or III), with Class I being least complicated (e.g., band-aids) and III being the most complicated (e.g., implantable defibrillators). The FDA stated that it would do two things: (1) update the language for consumers on the FDA website, as it previously claimed that there are no safety risks associated with mercury fillings, and (2) commit to classifying amalgams by July 28, 2009, the one year anniversary of the end of the public comment period. Currently amalgams are classified as Class I, with other low risk products such as bed pans and band-aids. We believe there is a good chance that the FDA will upgrade the classification to Class II.

- FDA issued a notice on April 28th, asking for comments on its intent to regulate mercury fillings. The FDA has asked for 90 days of comments on an original rule issued in 2002, proposing that the agency: (1) issue a separate classification regulation for encapsulated amalgam alloy and dental mercury; (2) amend the classification for amalgam by adding special controls; and (3) reclassify dental mercury from Class I to Class II.

- We do not believe that FDA will ban mercury fillings altogether, but it will likely restrict use in vulnerable populations. We do believe that the agency will ask for the label to indicate that mercury is an ingredient in the filling, and that special populations should be exempt from such fillings, such as: nursing women, pregnant women, young children, and immunocompromised individuals.

- Mercury fillings remain in the spotlight, given the link to certain neurological disorders. In November 2006, the FDA convened an advisory committee, in which the panel generally agreed that there is little evidence that dental amalgams cause health problems in a majority of the population. However, at the time, several panelists asked for label changes, as well as more data on specific health effects of mercury fillings on pregnant women, small children, and sensitive individuals. Mercury, more broadly, has been linked to disorders such as MS and there is now growing concern about the long-term health implications associated with older fillings. While it is too early to know whether a class action lawsuit will emerge, this could clearly raise the profile of the issue. In the interim, as it relates to our companies under coverage, we see a modest positive for suppliers of CAD/CAM and related equipment (i.e. Sirona), as patients proactively seek to remove amalgam fillings, and older teeth, due to the unknown health effects. Given that a large percentage of the patients are likely to be older (i.e. with brittle teeth), this could also drive increased volumes for bridge and crown repair work, and thereby, the need for more in-office equipment.
FDA Action on Mercury Fillings

In February 2002, FDA published a proposed rule entitled “Dental Devices: Classification of Encapsulated Amalgam Alloy and Dental Mercury and Reclassification of Dental Mercury; Issuance of Special Controls for Amalgam Alloy.”

In that document, FDA proposed the following actions:

- issue a separate classification regulation for encapsulated amalgam alloy and dental mercury;
- amend the classification for amalgam alloy by adding special controls; and
- reclassify dental mercury from class I to class II.

FDA proposed that all three products would have the same labeling guidance as a special control. In addition, FDA proposed that dental mercury would have a voluntary American National Standards Institute (ANSI) standard as a special control; encapsulated amalgam alloy and dental mercury would have voluntary ANSI and International Standards Organization (ISO) standards as special controls; and the amalgam alloy products would have a voluntary ISO standard as a special control.

Since 2002, a 2006 joint meeting of the Dental Products Panel and the Peripheral and Central Nervous System Drugs Advisory Committee raised the need for FDA to further consider scientific issues that are potentially relevant to this classification. The FDA provided a “White Paper” for Panel consideration, which selected 34 studies out of many hundreds that fulfilled the criteria for inclusion. Following a review and discussion, the Joint Panel voted 13-7 to reject the FDA conclusion that amalgam was safe. By the same voting margin, the panel also concluded that the paper did not objectively and clearly present the current state of knowledge about mercury exposure and health effects of dental amalgam. The panel did not say amalgam was unsafe, only that safety could not be established based upon data provided.

As a result, on April 28th, the FDA issued a federal register notice seeking 90 days of additional comments on the proposed classification. The comment period closes on July 28th. In response to a district court case, the FDA this week stated that it will classify mercury fillings by July 28, 2009. We believe the agency will limit usage of mercury fillings, but not ban use altogether.

The FDA comment period closes on July 28th. The FDA has stated it will classify mercury fillings by July 28, 2009. We believe the agency will limit usage of mercury fillings, but not ban use altogether.

FDA is now asking for comments concerning whether these devices should be classified into class II (special controls). Also, if class II is the appropriate classification for these devices, FDA requests comment on whether the two types of special controls proposed by FDA in 2002 (i.e. materials and labeling) provide reasonable assurance of the safety and effectiveness of the devices, and on whether the proposed special control guidance document should be revised in light of the recommendations and with respect to the discussions by the 2006 joint committee.

- Controls on the Materials. For example, should the material controls proposed by FDA address conformance to recognized consensus standards that make
recommendations for testing, compressive strength, and identifying the mercury vapor released by the device?

- **Labeling Controls.** For example, how should labeling controls, if any, address the disclosure of composition, including mercury content, and precautions regarding use of the device in sensitive subpopulations composed of individuals who respond biologically at lower levels of exposure to mercury than the general population? If so, which subpopulations should be included (e.g., children under age 6, pregnant and lactating women, hypersensitive, immunocompromised individuals)? Should the labeling controls require more specific patient labeling (e.g., informing patients of identified sensitive subpopulations of the mercury content, the alternatives to the device and their relative costs, and health risks associated with the failure to obtain dental care)?

On April 28, FDA also requested comments, including available data, on the following questions:

(1) How many annual procedures use mercury amalgams? What are the trends?

(2) What are the differences in cost between amalgams and alternative materials (e.g., composite, other metals, ceramics, etc.)? Are there differences in replacement lives?

(3) What are reimbursement rates for dental amalgam and the alternative materials?

(4) How would labeling describing the risks of amalgam for certain subpopulations (e.g., children under age 6, pregnant and lactating women, hypersensitive or immunocompromised individuals) affect the demand for, and use of, mercury amalgam? How would the risks included in the labeling be communicated to those subpopulations?

(5) What is the current exposure to mercury for patients? For professionals? What would be the reduction in exposure associated with the alternatives described previously?

**SOURCE:** Federal Register, v73, n82

Other Jurisdictions

In Asia, Japan remains the only country to regulate the use of amalgam fillings. Within Europe, the use of amalgam fillings varies greatly by country, with unrestricted use in certain countries (UK, France, Italy) and as such, and there is no clear precedent for the U.S. Other countries, notably Austria and Germany, have some restrictions on dental amalgam, such as permitting use for the general population, but not for children, pregnant women, people with kidney problems, when in contact with other metals (such as braces), and in people with mercury sensitivity. Sweden and Finland have banned or regulated the use of mercury in dental amalgams, citing health or environmental concerns, while amalgam use in Norway has been banned as of January 1, 2008. Of note is that the Swedish rationale is that “there are strong grounds for banning amalgam for environmental reasons. From a health point of view there is every reason to apply a precautionary approach.”
Moms Against Mercury vs. FDA

In mid-May 2008, a District Court in Washington, DC, required the FDA to respond with a date certain that it will classify mercury fillings.

This week, the FDA settled the court case in Judge Huvelle’s courtroom with the following commitments:

1. The FDA will classify mercury fillings by July 28, 2009 and
2. The FDA will update the information to consumers on its website (see link below).

As a reminder, Class I devices are subject to the least regulatory control. They present minimal potential for harm to the user and are often simpler in design than Class II or Class III devices. Class I devices are subject to “General Controls” as are Class II and Class III devices.

Class II devices are those for which general controls alone are insufficient to assure safety and effectiveness, and existing methods are available to provide such assurances. In addition to complying with general controls, Class II devices are also subject to special controls. Special controls may include special labeling requirements, mandatory performance standards and post-market surveillance.

We believe that the FDA is likely to classify mercury fillings as Class II devices. Class III is the most stringent regulatory category for devices. Class III devices are those for which insufficient information exists to assure safety and effectiveness solely through general or special controls. Examples include drug eluting stents and defibrillators.

Next Steps

Stakeholders will provide comments to the FDA as per the April 28th Federal Register notice. The comment period will close on July 28, 2008.

The FDA will have one year – until July 28, 2009 – to decide how it will classify mercury fillings, e.g., class I, II or III. Currently they are classified as Class I, with other low risk products such as bed pans and band-aids. We believe there is a good chance that the FDA will upgrade the classification to Class II.

In the meantime, the FDA has updated the website, as the old website language for consumers stated that mercury fillings are safe and contain no health risks: http://www.fda.gov/cdrh/consumer/amalgams.html. Notably, the FDA took only a few hours to update the website after the case was settled this week.

Background

Amalgam

Amalgam is a mixture of mercury (43-54%), silver, tin and copper with trace amounts of zinc indium and palladium added to increase strength and to reduce corrosion. While the integrity of the filling comes from the silver, mercury (as the
only metal liquid at room temperature) is required to activate the reaction to form the amalgam so that it can conform to the shape of the cavity and then set. Amalgam was first introduced in 1826 with 8 times the mercury content, with the current mercury levels stable since 1963.

### Amount of Mercury Released From Amalgam

Over the past several years, there has been growing concern over the use of mercury in dental amalgams, which make up nearly half the content of fillings, along with silver, tin and other elements, due to concerns over both patient safety (i.e. neurological, MS, teratogenic potential), as mercury is a known neurotoxin, with known environmental hazards. At issue is not whether the fillings are effective, but the fact that amalgam releases mercury vapor. While the scientific community generally agrees that amalgam fillings expose patients to a daily dose of mercury, different studies reviewed by the FDA have concluded that the exposure may be as low as 1-3 µg/day or as high as 27 µg/day, with compounding variables related to location and number of fillings, gum chewing and the frequency of teeth grinding.

The World Health Organization (WHO) has also reviewed the issue, with daily mercury exposure estimates ranging from 3 µg/day to 9 µg/day, with spikes in mercury release after chewing, eating or brushing teeth although it is unknown what portion of an inhaled dose is ingested rather than exhaled. A study by Berglund (J Dent Res 69:1646, 1990) measured the intraoral vapor levels over a 24-hour period in patients with at least nine amalgam restorations. The average daily dose of inhaled mercury vapor was 1.7 µg (range from 0.4 to 4.4 µg), which is approximately 1% of the threshold limit value of the 2µg/kg/day established by the World Health Organization, based on a maximum allowable environmental level of 50 µg/day.

Peer reviewed literature differs in the conclusions reached, with the range of opinions from “the current data are insufficient to support an association between mercury release from dental amalgam and the various complaints that have been attributed to this restoration material” (Life Sciences Research Office) to “removal of dental amalgam leads to permanent improvement of various chronic complaints in a relevant number of patients in various trials”(Freiburg University Institute for Environmental Medicine). Given what appears to be, at the very least, growing concerns over the link between mercury and diseases such as MS, we feel that this could drive a large number of patients proactively removing older fillings.

### Safety of Mercury

Two recent randomized clinical trials in children showed no statistically significant differences in adverse neuropsychological or renal effects observed over the five-year period in children whose caries were restored using dental amalgam or composite materials, although one study could not rule out the possibility of a small adverse effect on IQ in children with amalgam. In contrast, another study showed a trend of higher dental treatment need later in children with composite dental fillings, and thus, claimed that amalgam fillings are more durable. However, a subsequent study published in JAMA cites increased mercury blood levels in children with amalgam fillings. The study states, “during follow-up [blood mercury levels were] 1.0 to 1.5 µg higher in the amalgam group than in the composite group.” EPA considers high blood mercury levels to be harmful to fetus, and also states that “exposure at high levels can harm the brain, heart, kidneys, lungs, and immune
system of people of all ages.” Currently, EPA has set the “safe” mercury exposure level to be at 5.8 micrograms of mercury per one liter of blood.

In the longer term safety analysis in children there has been a drop in mercury excretion in urine, which also has resulting in conflicting opinions as some attribute this to a decrease in mercury in children’s bodies, whereas a response in JAMA says that this is evidence that children are losing the ability to excrete mercury with increased levels of exposure, and therefore mercury in the blood and muscle are better assessments of cumulative dose.

An analysis of the data collected during the studies showed that the authors of the studies ignored the drop in mercury excretion, after two years, in the urine in the children with amalgam fillings, even though the mercury exposure from amalgam remained the same or increased. This is explained in a response by Dr. Boyd Haley, to the 2006 publication, in JAMA, of the NIDCR-funded children's amalgam study. According to Haley, this is evidence that these children are losing the ability to excrete mercury with increased exposure. This observation points to a strong limitation in the use of mercury concentrations within urine as an indicator of mercury exposure from amalgam (and, potentially, as an indicator of mercury concentration within the bloodstream).

**Impact on the Dental Market**

As a result, while mercury-based amalgams have been the preferred restoration material for fillings for nearly a century and a half, and an estimated 30-50% of dentists are now “mercury free”, a large population of patients are increasingly looking to remove older fillings. Perhaps more importantly, the ADA, FDA and various advocacy groups are actively revisiting the issue as well, with a chance that the FDA could look to re-classify dental amalgam as a higher level (Class II or III) device, as due to the neurotoxic effects.

While it remains unclear whether mercury fillings will ultimately be banned, we expect an increasing shift toward crowns (using composite materials), as patients look for a longer-term replacement for fillings. We expect this could also drive higher demand for chair-side CAD/CAM procedures, as patients (in particular, elderly patients) seek the additional convenience of a single-visit approach. The American Dental Association has held that dental amalgam was safe since its foundation in 1859 as amalgam is durable, cheap, and easy to use although up until 1984 their position had been that no mercury could ever be released from amalgam as it was permanently bound. Resin composites are thought to be less durable than amalgam, however the gap between amalgam and composites durability appears to be closing as seen in follow up work published in JADA in 2007 which showed that in a study of 5000 children that resin based restorations had greater replacement rates than amalgam but was only statistically significant in patients with recurrent cavities.

As a caveat however, there are concerns as well in the literature about the estrogen-mimicking effects of the plastic chemicals such as Bisphenol A used in some composite resins.
Analyst Certification:
The research analyst(s) denoted by an “AC” on the cover of this report certifies (or, where multiple research analysts are primarily responsible for this report, the research analyst denoted by an “AC” on the cover or within the document individually certifies, with respect to each security or issuer that the research analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers; and (2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report.

Important Disclosures

Price Charts for Compendium Reports:  Price charts are available for all companies under coverage for at least one year through the search function on JPMorgan’s website https://mm.jpmorgan.com/disclosures/company or by calling this toll free number (1-800-477-0406).

Explanation of Equity Research Ratings and Analyst(s) Coverage Universe:
JPMorgan uses the following rating system: Overweight [Over the next six to twelve months, we expect this stock will outperform the average total return of the stocks in the analyst’s (or the analyst’s team’s) coverage universe.] Neutral [Over the next six to twelve months, we expect this stock will perform in line with the average total return of the stocks in the analyst’s (or the analyst’s team’s) coverage universe.] Underweight [Over the next six to twelve months, we expect this stock will underperform the average total return of the stocks in the analyst’s (or the analyst’s team’s) coverage universe.] The analyst or analyst’s team’s coverage universe is the sector and/or country shown on the cover of each publication. See below for the specific stocks in the certifying analyst(s) coverage universe.

| JPMorgan Equity Research Ratings Distribution, as of March 31, 2008 |
|--------------------------------------|---------|---------|---------|
| JPM Global Equity Research Coverage  | 46%     | 41%     | 13%     |
| IB clients*                         | 50%     | 51%     | 39%     |
| JPMSSI Equity Research Coverage     | 41%     | 47%     | 11%     |
| IB clients*                         | 70%     | 66%     | 54%     |

*Percentage of investment banking clients in each rating category.

For purposes only of NASD/NYSE ratings distribution rules, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category.

Valuation and Risks:  Please see the most recent company-specific research report for an analysis of valuation methodology and risks on any securities recommended herein. Research is available at http://www.morganmarkets.com, or you can contact the analyst named on the front of this note or your JPMorgan representative.

Analysts’ Compensation: The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Institutional Equities and Investment Banking.

Other Disclosures

Options related research: If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the Option Clearing Corporation’s Characteristics and Risks of Standardized Options, please contact your JPMorgan Representative or visit the OCC’s website at http://www.optionsclearing.com/publications/risks/riskstoc.pdf.

Legal Entities Disclosures

U.S.: JPMSSI is a member of NYSE, FINRA and SIPC. J.P. Morgan Futures Inc. is a member of the NFA. JPMorgan Chase Bank, N.A. is a member of FDIC and is authorized and regulated in the UK by the Financial Services Authority. U.K.: J.P. Morgan Securities Ltd. (JPMSL) is a member of the London Stock Exchange and is authorised and regulated by the Financial Services Authority. Registered in England & Wales No. 2711006. Registered Office 125 London Wall, London EC2Y 5AJ. South Africa: J.P. Morgan Equities Limited is a member of the Johannesburg Securities Exchange and is regulated by the FSB. Hong Kong: J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong. Korea: J.P. Morgan Securities (Far East) Ltd, Seoul branch, is regulated by the Korea Financial Supervisory Service. Australia: J.P. Morgan Australia Limited (ABN 52 002 888 011/AFS Licence No: 238188) is regulated by ASIC and J.P. Morgan Securities Australia Limited (ABN 61 003 245 234/AFS Licence No: 238066) is a Market Participant with the ASX and regulated by ASIC. Taiwan: J.P. Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock
Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. **India:** J.P. Morgan India Private Limited is a member of the National Stock Exchange of India Limited and The Stock Exchange, Mumbai and is regulated by the Securities and Exchange Board of India. **Thailand:** JPMorgan Securities (Thailand) Limited is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission. **Indonesia:** PT J.P. Morgan Securities Indonesia is a member of the Jakarta Stock Exchange and Surabaya Stock Exchange and is regulated by the BAPEPAM. **Philippines:** J.P. Morgan Securities Philippines Inc. is a member of the Philippine Stock Exchange and is regulated by the Securities and Exchange Commission. **Brazil:** Banco J.P. Morgan S.A. is regulated by the Comissao de Valores Mobiliarios (CVM) and by the Central Bank of Brazil. **Mexico:** J.P. Morgan Casa de Bolsa, S.A. de C.V., J.P. Morgan Grupo Financiero is a member of the Mexican Stock Exchange and authorized to act as a broker dealer by the National Banking and Securities Exchange Commission. **Singapore:** This material is issued and distributed in Singapore by J.P. Morgan Securities Singapore Private Limited (JPMSS) [mica (p) 207/01/2008 and Co. Reg. No.: 199405335R] which is a member of the Singapore Exchange Securities Trading Limited and is regulated by the Monetary Authority of Singapore (MAS) and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore) which is regulated by the MAS. **Malaysia:** This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-x) which is a Participating Organization of Bursa Malaysia Securities Bhd and is licensed as a dealer by the Securities Commission in Malaysia. **Pakistan:** J. P. Morgan Pakistan Broking (Pvt.) Ltd is a member of the Karachi Stock Exchange and regulated by the Securities and Exchange Commission of Pakistan.

**Country and Region Specific Disclosures**

**U.K. and European Economic Area (EEA):** Issued and approved for distribution in the U.K. and the EEA by JPMSL. Investment research issued by JPMSL has been prepared in accordance with JPMSL’s Policies for Managing Conflicts of Interest in Connection with Investment Research which outline the effective organisational and administrative arrangements set up within JPMSL for the prevention and avoidance of conflicts of interest with respect to research recommendations, including information barriers, and can be found at http://www.jpmorgan.com/pdfdoc/research/ConflictManagementPolicy.pdf. This report has been issued in the U.K. only to persons of a kind described in Article 19 (5), 38, 47 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons being referred to as "relevant persons"). This document must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is only available to relevant persons and will be engaged in only with relevant persons. In other EEA countries, the report has been issued to persons regarded as professional investors (or equivalent) in their home jurisdiction **Germany:** This material is distributed in Germany by J.P. Morgan Securities Ltd. Frankfurt Branch and JPMorgan Chase Bank, N.A., Frankfurt Branch who are regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht. **Australia:** This material is issued and distributed by JPMAL in Australia to “wholesale clients” only. JPMAL does not issue or distribute this material to “retail clients.” The recipient of this material must not distribute it to any third party or outside Australia without the prior written consent of JPMAL. For the purposes of this paragraph the terms “wholesale client” and “retail client” have the meanings given to them in section 761G of the Corporations Act 2001. **Hong Kong:** The 1% ownership disclosure as of the previous month end satisfies the requirements under Paragraph 16.5(a) of the Hong Kong Code of Conduct for persons licensed by or registered with the Securities and Futures Commission. (For research published within the first ten days of the month, the disclosure may be based on the month end data from two months’ prior.) J.P. Morgan Broking (Hong Kong) Limited is the liquidity provider for derivative warrants issued by J.P. Morgan International Derivatives Ltd and listed on The Stock Exchange of Hong Kong Limited. An updated list can be found on HKEx website: http://www.hkex.com.hk/prod/dw/Lp.htm. **Japan:** There is a risk that a loss may occur due to a change in the price of the shares in the case of share trading, and that a loss may occur due to the exchange rate in the case of foreign share trading. In the case of share trading, JPMorgan Securities Japan Co., Ltd., will be receiving a brokerage fee and consumption tax (shouhizei) calculated by multiplying the executed price by the commission rate which was individually agreed between JPMorgan Securities Japan Co., Ltd., and the customer in advance. Financial Instruments Firms: JPMorgan Securities Japan Co., Ltd., Kanto Local Finance Bureau (kinsho) No. [82] Participating Association / Japan Securities Dealers Association, The Financial Futures Association of Japan. **Korea:** This report may have been edited or contributed to from time to time by affiliates of J.P. Morgan Securities (Far East) Ltd, Seoul branch. **Singapore:** JPMAL and/or its affiliates may have a holding in any of the securities discussed in this report; for securities where the holding is 1% or greater, the specific holding is disclosed in the Legal Disclosures section above. **India:** For private circulation only not for sale. **Pakistan:** For private circulation only not for sale. **New Zealand:** This material is issued and distributed by JPMAL in New Zealand only to persons whose principal business is the investment of money or who, in the course of and for the purposes of their business, habitually invest money. JPMAL does not issue or distribute this material to members of “the public” as determined in accordance with section 3 of the Securities Act 1978. The recipient of this material must not distribute it to any third party or outside New Zealand without the prior written consent of JPMAL.

**General:** Additional information is available upon request. Information has been obtained from sources believed to be reliable but JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively JPMorgan) do not warrant its completeness or accuracy except with respect to any disclosures relative to JPMI and/or its affiliates and the analyst’s involvement with the issuer that is the subject of the research. All pricing is as of the close of market for the securities discussed, unless otherwise stated. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. JPMI distributes in the U.S. research published by non-U.S. affiliates and accepts responsibility for its contents. Periodic updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other publicly available information. Clients should contact analysts and execute transactions through a JPMorgan subsidiary or affiliate in their home jurisdiction unless governing law permits otherwise.

“Other Disclosures” last revised February 6, 2008.
Copyright 2008 JPMorgan Chase & Co. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of JPMorgan.